Baclofen

Play pronunciation

Generic name:[al-B-o-klo-fen]Other brand namesof baclofen include:BACLOFEN (t-BAL-fen)

Medically reviewed by. Last updated on Jan 1, 2025.

What is baclofen?

Baclofen is used to treat muscle spasticity caused by multiple sclerosis, spinal cord injury, or other spinal injuries. Baclofen is also used to treat certain types of spasticity that may be caused by multiple sclerosis or spinal cord injury. Baclofen may also be used to treat spasticity caused by injury to the arms, legs, and other body parts.

Baclofen may also be used to treat high blood pressure, high cholesterol, or diabetes.

Uses of Baclofen

Baclofen is used to treat muscle spasticity that may be caused by multiple sclerosis, spinal cord injury, or other spinal injuries. Baclofen is also used to treat certain types of spasticity that may be caused by spinal cord injuries.

Precautions

Baclofen may cause the following:

• Symptoms may include muscle stiffness, muscle spasm, tightness, muscle jerks, weakness, and cramps; muscle spasm may occur as a side effect; muscle spasms may also occur in people with cerebral palsy; and increased muscle tone may occur with high blood pressure or high cholesterol.

Baclofen may also cause the following symptoms to occur in people with muscle spasticity caused by multiple sclerosis:

• Frequent muscle stiffness may occur; spasms may also occur in people with cerebral palsy; and weakness may occur.
• Muscle stiffness may occur as a side effect. Muscle stiffness may also occur with or without fever.
• Increased muscle tone may occur with high blood pressure or high cholesterol.
• Muscle spasms may also occur as a side effect, and muscle spasms may occur at a higher rate than usual.

If you are experiencing a muscle stiffness that may be caused by the following symptoms, contact your doctor:

• Feeling light-headed or weak; painful or difficult to breathe; a racing heart, irregular heartbeat, muscle twitching; a sudden change in color or texture, feeling cold, or feeling tired.
• Stomach pain or cramps may occur. These symptoms may be worse if you have a spinal cord injury.
• Feeling tired and weak, and not being able to move, can also occur.
• You may feel more anxious or nervous about going to the toilet or using a toilet seat, especially when you first start to feel sick.
• You may also feel dizzy or light-headed when you first see a doctor. This could be a sign that your body is not responding to the medicine. Get up slowly when rising from a sitting or lying position.
• You may feel as though you are being sick or being sick too quickly. This could be because of the medicine or because of the increased strain on your heart or because of your body’s reaction to the medicine.
• The muscles may get stiff and stiff, especially the calves and legs. Muscle spasms may occur as a side effect of Baclofen. These spasms may be caused by multiple sclerosis, spinal cord injury, or other spinal injuries. These spasms can also occur with other injuries to the arms, legs, and other body parts.
• The muscle may become very tight or stiff and sometimes painful. Your doctor may suggest you speak with your doctor about how your muscles may be stiff and stiff.

Warnings

Baclofen may cause an increased risk of serious muscle spasms, especially if you are taking the following:

• Blood pressure medicine: If you are taking the blood pressure medicine and have a blood pressure of 150/90 mmHg or higher, your doctor will tell you to avoid taking blood pressure medicine and to take Baclofen with food or milk.

A new study, published in the New England Journal of Medicine, says that the GABAB receptors (GABAB1 andGABAB2), which play a role in the brain’s reward signals, are more likely to be activated by the drug than by the GABAB agonist baclofen. The authors found that those on baclofen, or the GABAB receptor, had a higher incidence of GABAB receptor activation. The same authors reported that baclofen, or the GABAB receptor agonist baclofen, had the greatest effect on the GABAB receptor-induced GABAB agonist-dependent effect.

“GABAB agonist drugs, including GABAB receptor agonists, are widely available in the market, but many patients still require their use in order to avoid drug interactions,” said Dr. Paul D. Ryan, a urologist at the University of California, San Francisco School of Medicine and a professor of urology at the University of Minnesota. “There is no way to predict how a patient will respond to a drug, so patients often have to choose between the two.”

This is the latest in a series of recent studies that examine the GABAB receptors, the two most important of which are the GABAB receptor and the GABAB agonist.

The most common GABAB agonist, baclofen, has been associated with a high risk of heart attack and stroke. In addition to the GABAB receptor, the GABAB agonist also has a number of other effects on the brain. The GABAB receptor is involved in the production of dopamine, a neurotransmitter that controls mood, behavior, and learning. GABAB agonists have also been linked to a number of other side effects, including central nervous system disorders and depression.

A study of the effect of baclofen on the GABAB receptor on a large group of patients found that the effect of baclofen was greater than that of the drug on their GABAB receptors. The investigators found that a third of the patients who were given baclofen had a decrease in their GABAB receptors. The study also found that baclofen caused a decrease in the number of GABAB receptors in the dorsal raphe and spinal cord.

“This finding is exciting news for the researchers in this area, because baclofen has been shown to have a number of other benefits for patients, such as enhancing the function of GABAB receptors,” said Dr.

The study was published in the May/June issue of the New England Journal of Medicine.

“This study shows that the GABAB receptor is more likely to be activated by baclofen than by the GABAB agonist,” Dr. Ryan said. “This finding is interesting because GABAB receptors are involved in many of the functions of the central nervous system, and many of these other effects are involved in the control of learning and memory.”

“There is no way to predict how a patient will respond to a drug, so patients often have to choose between the two,” Dr.

The GABAB receptors are important for the brain to receive signals and play a key role in the pleasure, reward, and motivation of the brain. When GABAB agonists are prescribed for a chronic condition, their levels of activity are increased, which in turn is associated with an increase in the activity of the GABAB receptor. The GABAB receptor is also involved in the pleasure of the brain. Studies have shown that the GABAB receptors are more likely to be activated by baclofen than by the GABAB agonist, leading to the same effect.

The study is the first to look at the GABAB receptor and the GABAB agonist, and to determine how baclofen and other drugs affect the GABAB receptors in the brain.

Dr. Ryan and his colleagues compared data from two large clinical trials of baclofen, which is used to treat muscle spasticity. The studies examined 824 patients with spasticity and 12 healthy subjects.

Introduction

Intrathecal Baclofen (ITB) is a novel type of drug with a novel mechanism of action. The main objective of ITB therapy is its fast action rate compared with traditional oral medications like oral antispasmodics. This study aimed to compare the efficacy and safety of ITB versus oral agents for patients with primary dysmenorrhea (PMDD) with or without other contraindications to ITB therapy.

This is a prospective, double-blind, placebo-controlled, randomized, controlled trial with a convenience of 4 weeks duration and open study design in the treatment of patients with primary dysmenorrhea (PMDD) and other contraindications to ITB therapy.

Efficacy and safety

The primary efficacy measure was the change from baseline in global health measured by the Global Assessment for Dysmenorrhea (GAD) scale using the Modified Global Assessment (MGAD) scale. Secondary efficacy measures included the change from baseline in global health (the number needed to treat [NNT] for each symptom compared to baseline), change from baseline in global health (the number needed to treat [NNT] for each symptom compared to baseline) and change from baseline in global health (the number needed to treat [NNT] for each symptom compared to baseline) after 4 weeks.

The efficacy in primary dysmenorrhea was assessed using the Modified Menopausal Symptoms (MMS) questionnaire.

The efficacy in dysmenorrhea was assessed using the Modified International Index of Erectile Function (MIEF) domain and the Global Assessment for Dysmenorrhea (GAD) domain. The MMS and the global health domain were assessed with the EuroQol 5-5 Lik-off and the Global Assessment for Menopausal Symptoms (IGALS) questionnaire.

The efficacy in PMDD was assessed with the MMS and the GAD domain.

The primary and secondary end points were the change from baseline to end of treatment (time to treatment, number needed to treat [NNT], symptom score, number needed to treat [NNT], symptom score on the GAD and MMS questionnaire) and the number needed to treat for each symptom.

Patients

The patients who were eligible to participate in the study were between 18 and 64 years of age who had been diagnosed with primary dysmenorrhea (PMDD) and had no other contraindications to ITB therapy. Those who had undergone a hysterectomy or other surgical treatment with a combination of oral antibiotics were excluded from the study. Those who were enrolled in the study were excluded if they:

• were female, had a body mass index (BMI) >30 kg/m2, had no other contraindication to ITB therapy and were taking a prescription medication for pain control
• were using any medication for anxiety, depression or mood disorders
• were taking any medication for hepatitis C
• were on any other treatment for epilepsy or epilepsy associated with severe pain or neurological disorders
• were on any medication for hepatitis A

Patients who were excluded because of hypersensitivity to ITB, systemic conditions, severe hepatic impairment, or previous adverse reactions were also excluded.

Primary efficacy measure

The change from baseline to treatment was measured using the Modified Global Assessment (MGAD) domain. The mean change from baseline to treatment was assessed by the International Index of Erectile Function (IIEF) questionnaire and the score on the MMS was assessed by the MMS questionnaire.

The MMS and the global health domain were assessed by the EuroQol 5-5 Lik-off and the MMS questionnaire.

Safety

Safety in patients with primary dysmenorrhea (PMDD) and other contraindications to ITB therapy was assessed.

Interaction

The primary interaction between ITB and oral agents was not statistically significant.

Duration of effect

The duration of effect ranged from 5 to 20 weeks (median: 7 weeks) with a mean change from baseline of 2.5 ± 1.7. The mean change from baseline to treatment was 3.5 ± 1.7. The mean change from baseline to treatment was 3.4 ± 1.6. The mean change from baseline to treatment was 1.5 ± 1.2.

Interaction type

The type of interaction between ITB and oral agents was not statistically significant.

Baclofen is a muscle relaxant. It is used in the treatment of spasticity in patients with multiple sclerosis, spinal cord injury or other spasticity. Baclofen can be taken in different doses, but it is usually taken at the same time every day. Baclofen is usually well tolerated. Baclofen can cause drowsiness, tiredness and a sensation of having something wrong with your body. If you have any of these symptoms, tell your doctor right away. Tell your doctor right away if you have any side effects, such as muscle weakness, muscle pain, cramps or stiffness, numbness, pain, tingling, muscle pain or tightness in your arms, legs or neck, or muscle pain with or without cold symptoms (feeling that you are being exposed). Drowsiness may occur. Alcohol- or drug-induced drowsiness may also occur. This can occur. Alcohol and drug induced drowsiness may also occur. Tell your doctor if you have any unusual vision or hearing loss. These effects are likely to be permanent. Do not drive or operate machinery until you know how the effects of this medicine will affect you. Limit alcohol consumption while you are on Baclofen and tell your doctor right away if you are dehydrated or have stomach ulcers, or if you have or have had stomach bleeding. If you drink alcohol while you are on Baclofen tell your doctor right away. To lessen the chance of dizziness, avoid sitting up until you finish your speaking program, and only use the first two or three times in the morning and in the evening. To lessen the chance of getting tired, rest, change positions slowly, and do not drive or operate machinery until you know how the effects of this medicine will affect you. Limit alcohol consumption while you are on Baclofen and tell your doctor right away if you are dehydrated or have stomach ulcers, to lessen the chance of dizziness, rest, change positions slowly, and do not drive or operate machinery until you know how the effects of this medicine will affect you. Alcohol and drug induced drowsiness may occur.